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IMPORTANCE The appropriate duration of antibiotics for staphylococcal bacteremia is unknown.
OBJECTIVE To test whether an algorithm that defines treatment duration for staphylococcal
bacteremiavsstandardofcareprovidesnoninferiorefficacywithoutincreasingsevereadverseevents.
DESIGN, SETTING, AND PARTICIPANTS A randomized trial involving adults with staphylococcal
bacteremia was conducted at 16 academic medical centers in the United States (n = 15) and
Spain (n = 1) from April 2011 to March 2017. Patients were followed up for 42 days beyond end
of therapy for those with Staphylococcus aureus and 28 days for those with coagulase-negative
staphylococcal bacteremia. Eligible patients were 18 years or older and had 1 or more blood
cultures positive for S aureus or coagulase-negative staphylococci. Patients were excluded if
they had known or suspected complicated infection at the time of randomization.
INTERVENTIONS Patients were randomized to algorithm-based therapy (n = 255) or usual
practice (n = 254). Diagnostic evaluation, antibiotic selection, and duration of therapy were
predefined for the algorithm group, whereas clinicians caring for patients in the usual practice
group had unrestricted choice of antibiotics, duration, and other aspects of clinical care.
MAIN OUTCOMES AND MEASURES Coprimary outcomes were (1) clinical success, as
determined by a blinded adjudication committee and tested for noninferiority within a 15%
margin; and (2) serious adverse event rates in the intention-to-treat population, tested for
superiority. The prespecified secondary outcome measure, tested for superiority, was
antibiotic days among per-protocol patients with simple or uncomplicated bacteremia.
RESULTS Among the 509 patients randomized (mean age, 56.6 [SD, 16.8] years; 226 [44.4%]
women), 480 (94.3%) completed the trial. Clinical success was documented in 209 of 255
patients assigned to algorithm-based therapy and 207 of 254 randomized to usual practice
(82.0% vs 81.5%; difference, 0.5% [1-sided 97.5% CI, −6.2% to ]). Serious adverse events
were reported in 32.5% of algorithm-based therapy patients and 28.3% of usual practice
patients (difference, 4.2% [95% CI, −3.8% to 12.2%]). Among per-protocol patients with simple
or uncomplicated bacteremia, mean duration of therapy was 4.4 days for algorithm-based
therapy vs 6.2 days for usual practice (difference, −1.8 days [95% CI, −3.1 to −0.6]).
CONCLUSIONS AND RELEVANCE Among patients with staphylococcal bacteremia, the use of
an algorithm to guide testing and treatment compared with usual care resulted in a
noninferior rate of clinical success. Rates of serious adverse events were not significantly
different, but interpretation is limited by wide confidence intervals. Further research is
needed to assess the utility of the algorithm.
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S taphylococci are the most commonly identified patho-gens in both hospital-acquired and community-onsetbloodstream infections.1 Despite its frequency, the op-
timal duration of treatment for staphylococcal bacteremia is
unknown. Consensus guidelines recommend prolonged
courses of antibiotics for complicated staphylococcal bacte-
remia and shorter courses of therapy for uncomplicated staphy-
lococcal bacteremia, but these are primarily based on low-
quality evidence and expert opinion.2-4 As a result, there is con-
siderable variation in treatment practices.5
Unnecessarily treating patients who have uncomplicated
staphylococcal bacteremia with prolonged courses of antibi-
otics leads to antibiotic overuse and increases the likelihood
for drug-related adverse events.6 By contrast, patients with
complicated staphylococcal bacteremia who incorrectly re-
ceive abbreviated courses of therapy are at risk for relapse, mor-
bidity, and mortality.7 A standardized strategy to classify pa-
tients with complicated and uncomplicated staphylococcal
bacteremia and treat them with the appropriate duration of an-
tibiotics would thus improve patient care.
This trial assessed the efficacy and safety of an algorithm
that defines treatment duration for staphylococcal bacte-
remia based on clinical characteristics and evaluated the ef-
fect of its use on the duration of antibiotic therapy.
Methods
Study Design
The trial protocol and statistical analysis plan are available in
Supplement 1. In brief, this multicenter open-label randomized
trial was conducted between April 2011 and March 2017 at 16 sites
in the United States and Spain. The institutional review board
at each site approved the study, and written informed consent
was obtained from all participants or their authorized represen-
tatives. The data were analyzed by study statisticians (S.C.C., J.G.)
in collaboration with all of the authors.
Eligible patients were 18 years or older and had 1 or more
blood cultures positive for either Staphylococcus aureus or
coagulase-negative staphylococci. Patients were excluded if
they had known or suspected complicated infection at the time
of randomization, had polymicrobial bacteremia with at least
1 nonstaphylococcal pathogen, or had creatinine clearance less
than 30 mL/min. Full eligibility criteria are listed in eAppen-
dix 1 in Supplement 2.
Patients were randomized to either algorithm-based
therapy or usual practice. Classification of bacteremia, anti-
biotic choice, and treatment duration were predefined for al-
gorithm patients (Table 1). All patients were required to have
follow-up blood cultures obtained every 24 to 48 hours until
clearance was documented. Care of patients in the usual prac-
tice group was otherwise unrestricted with regard to antibi-
otic choice, duration, and clinical management.
Definitions
Race and ethnicity were classified by the investigators, based
on categories defined by the National Institutes of Health (NIH),
as per NIH requirements. Patients were classified as having
simple, uncomplicated, or complicated bacteremia (Table 1)
according to signs or symptoms of local or metastatic sites of
infection on physical examination, number and timing of posi-
tive blood culture results, and echocardiography.
The intention-to-treat population included all randomized
patients. All patients in the intention-to-treat population were
included in the safety population. The per-protocol population
included all randomized patients except those who received a
potentially effective nonstudy antibiotic before final test of cure,
did not undergo removal of an intravenous catheter (with the
exception of patients with simple coagulase-negative staphylo-
coccal bacteremia, in whom the catheter could be retained), dis-
continued study medication prematurely for reasons other than
clinical failure, did not undergo final test-of-cure assessment,
violated inclusion/exclusion criteria or other key protocol ele-
ments, died within 3 days of randomization, or were classified
as nonevaluable. Nonevaluable was defined as failure for ad-
ministrative reasons, eg, patients who withdrew consent, dis-
continued treatment against medical advice, were withdrawn
from the study, or were lost to follow-up. Nonevaluable pa-
tients were considered to have experienced treatment failure in
the intention-to-treat analyses. Treatment failure was defined
as death, persistent or relapsing infection (eAppendix 2 in
Supplement 2), diagnosis of a complicated staphylococcal in-
fection after completion of antibiotic therapy, or change of treat-
ment because of unsatisfactory clinical response.
Randomization, Treatment, and Monitoring
Patients were assigned to algorithm-based therapy vs usual prac-
tice in computer-generated permuted randomized blocks by site,
with block sizes of 2, 4, or 6. Patients in the algorithm group were
treated with vancomycin or daptomycin for methicillin-resistant
staphylococci and an intravenous antistaphylococcal penicillin
or cefazolin for methicillin-susceptible staphylococci. Vancomy-
cin was dosed per local standard practice, with a recommenda-
tion that it be dosed in accordance with published guidelines.8
Vancomycinminimuminhibitoryconcentration(MIC)testingwas
performed at study sites per standard local practice.
The choice and duration of antibiotics in the usual prac-
tice group was determined by the treating physician. In
the algorithm group, duration of therapy was prespecified
Key Points
Question What is the effect of an algorithm used to define
antibiotic choice and duration on clinical success and serious
adverse events in patients with staphylococcal bacteremia?
Findings In this randomized trial that included 509 adults with
staphylococcal bacteremia, use of an algorithm compared with
usual care resulted in a clinical success rate of 82.0% vs 81.5%,
respectively, a difference that met the noninferiority margin of
15%. Serious adverse events occurred in 32.5% vs 28.3% of
patients, a difference that was not statistically significant
but with wide confidence intervals.
Meaning The use of an algorithm to guide testing and treatment
comparedwithusualcareresultedinanoninferiorrateofclinicalsuccess;
although there was not a significant difference in serious adverse
events, interpretation is limited by wide confidence intervals.
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by the algorithm-defined category (Table 1). Patients with
simple coagulase-negative staphylococcal bacteremia could
have received up to 3 days of treatment before randomiza-
tion (to account for empirical therapy before receipt of cul-
ture results). For patients with simple coagulase-negative
staphylococci randomized to the algorithm, antibiotics were
discontinued at randomization or not started if the patient had
not yet initiated antibiotic therapy at the time of randomiza-
tion. Patients with uncomplicated coagulase-negative staphy-
lococcal bacteremia who were randomized to the algorithm re-
ceived 5 days of parenteral therapy. Patients randomized to the
algorithm for uncomplicated S aureus bacteremia received 14
days of parenteral antibiotics.
Patients known or suspected to have complicated staphy-
lococcal bacteremia (either coagulase-negative staphylococci or
S aureus) at the time of randomization were ineligible for study
participation. If complicated bacteremia was recognized after
randomization but before completion of study treatment, the
patient was retained in the study and his or her care managed
for complicated bacteremia. Patients with complications diag-
nosed after the end of therapy were considered to have expe-
rienced treatment failure. Patients in the algorithm group with
complicated coagulase-negative staphylococci received 7 to 28
days of parenteral antibiotic therapy. Patients with compli-
cated S aureus bacteremia were treated for 28 to 42 days. An-
tibiotic days were calculated as the total duration of effective
antistaphylococcal antibiotics, beginning with the date of the
qualifying blood culture. Any day that a patient received a dose
of effective therapy was considered an antibiotic day.
Test-of-cure evaluation occurred 28 days after the end of
study antibiotic treatment for coagulase-negative staphylo-
coccal bacteremia and 42 days after the end of treatment for
S aureus bacteremia. To be considered cured, patients must
have had microbiologic and clinical resolution of bacteremia,
without relapse or development of new manifestations of
staphylococcal infection. Telephone test-of-cure evaluation
was permissible when a clinic visit was not possible.
Echocardiography
Echocardiography was required for all patients in the
algorithm-based therapy group who had S aureus bacter-
emia. Transesophageal echocardiography was preferred.3 All
echocardiograms for patients in the algorithm-based therapy
group were reviewed by a study echocardiography core labo-
ratory. Echocardiography core laboratory interpretations were
blinded to treatment assignment, site interpretation, and clini-
cal details. Echocardiography for patients in the usual prac-
tice group was at the discretion of the local clinician.
Outcomes
Adjudication Committee
An adjudication committee of 3 experts (D.J.A., H.W.B., S.E.C.)
blinded to treatment assignment reviewed clinical data from
each patient to establish the primary clinical outcome (suc-
cess, failure, or nonevaluable). For all patients who died dur-
ing the study period, the adjudication committee blindly re-
viewed case records to establish whether the death was
attributable to the staphylococcal infection. The adjudica-
tion committee also reviewed all potentially effective non-
study antibiotics administered to each patient from random-
ization until test of cure to ensure that patient outcome was
solely attributable to the duration of study antibiotics.
Primary Outcomes
The primary outcomes in the intention-to-treat population
were (1) success rate at the test-of-cure evaluation and (2) in-
vestigator-reported serious adverse event rate in the 2 treat-
ment groups. The study would be considered negative if the
algorithm resulted in either inferior clinical outcomes (ie, lower
success rate) or a statistically higher rate of serious adverse
events. Patients were classified as having experienced treat-
ment success if they were judged to be cured by the adjudica-
tion committee and exhibited none of the criteria for failure
Table 1. Clinical Classification of Bacteremia







Intravascular catheter source of infection
(if present) removed within 5 d
Negative follow-up blood culture 24-72 h
after initial positive culture
Defervescence within 72 h of initial positive culture
Echocardiogram without evidence of endocarditis
No symptoms or signs of metastatic infection
No indwelling intravascular prosthetic devices
Complicated 28-42 (±2)
Positive follow-up blood culture for S aureus, OR
Persistent fever, OR
Echocardiography with evidence of endocarditis, OR
Symptoms or signs of metastatic infection
Coagulase-negative Staphylococcal Bacteremia
Simple 0-3 (+1)a
Single blood culture positive
for coagulase-negative staphylococci
Negative follow-up blood culture
No signs or symptoms of local infection
at a catheter site
No symptoms or signs of metastatic infection
No indwelling intravascular prosthetic devices
Uncomplicated 5 (±1)
≥2 blood cultures positive for coagulase-negative
staphylococci drawn ≤24 h apart, OR
Single blood culture positive for coagulase-negative
staphylococci, PLUS symptoms or signs of infection
at a catheter site
Complicated 7-28 (±2)
≥2 blood cultures positive for coagulase-negative
staphylococci from samples drawn >24 h apart, OR
Echocardiography with evidence of endocarditis, OR
Symptoms or signs of metastatic infection
a For patients with simple coagulase-negative staphylococcal bacteremia,
treatment was discontinued on randomization to algorithm-based therapy.
Thus, if clinicians suspected that the positive culture result was attributable to
contamination and had not initiated therapy, those patients did not receive
any study antibiotic therapy.
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or nonevaluable outcomes. Serious adverse events were those
adverse events that resulted in death; were life-threatening;
caused persistent or significant disability or incapacity; inpa-
tient hospitalization or prolongation of existing hospitaliza-
tion; congenital abnormality or birth defect; or were consid-
ered important medical events.
Secondary Outcome
The prespecified secondary outcome was antibiotic days in the
per-protocol population with simple or uncomplicated staphy-
lococcal bacteremia.
Exploratory Outcomes
Exploratory outcome measures included (1) cure rate and an-
tibiotic duration in both the intention-to-treat and per-
protocol populations among the following subgroups: all pa-
tients with coagulase-negative staphylococcus, the subgroups
with simple and uncomplicated coagulase negative staphylo-
coccus, all S aureus, and the subgroup with uncomplicated
S aureus; and (2) the association between vancomycin MIC and
clinical outcomes. A post hoc analysis of clinical success among
patients with complicated S aureus was also performed. The
frequency of mortality events judged to be attributable to
staphylococcal infection by the blinded adjudication review
was compared in the 2 treatment groups. This comparison was
not prespecified before trial initiation.
Statistical Analysis
Assuming a 75% cure rate in each treatment group, statistical
power of 90%, and a 2-sided significance level of .05, we esti-
mated that 362 patients would need to be enrolled to demon-
strate noninferiority within a margin of 15%, using the large-
sample z test. This margin was lower than that allowed in the
only previous S aureus bloodstream infection registrational trial9
and is consistent with contemporary noninferiority margins cur-
rently considered by the US Food and Drug Administration for
trials seeking an indication in S aureus bloodstream infection.
We additionally estimated that based on previous trial
experience,9 approximately 28% of enrolled patients would be
excluded from the per-protocol population. To have sufficient
power for the secondary outcome, a sample size of 500 pa-
tients was selected. The efficacy analyses are based on 97.5%
Figure. Flow of Participants Through the Staphylococcal Bacteremia Trial
23 666 Patients with positive blood culture
results assessed for eligibility
23 157 Excluded
22 030 Excluded on initial screen
1127 Excluded on secondary screen (unwilling or unable to
provide informed consent)
5419 Known or suspected complicated bacteremia
5182 Only single blood culture sample collecteda
3006 Creatinine clearance <30 mL/min
1211 Considered unlikely to adhere to study procedures
1077 Shock and/or high probability of death within 3 d
999 Nonremovable intravascular foreign material
985 Polymicrobial bacteremia
832 Received ≥7 d of antibiotics before blood culture
802 Suspected contaminant not requiring antibiotic therapya
800 Younger than 18 y
632 Neutropenia (exclusion for Staphylococcus aureus only)
625 Unwilling to have intravenous catheter removed
460 Other
509 Randomized
255 Included in primary analysis
207 Included in per-protocol populationb
254 Included in primary analysis
203 Included in per-protocol populationb
255 Randomized to receive algorithm-based therapy
255 Received intervention as randomized







57 Had S aureus bacteremia
4 Infected with nonstaphylococcal
species only
254 Randomized to receive usual practice
254 Received intervention as randomized







59 Had S aureus bacteremia
4 Infected with nonstaphylococcal
species only
a Prior to an amendment allowing inclusion of these patients.
b Details for reasons for exclusion from the per-protocol population are provided in eTable 8 in Supplement 2.
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1-sided testing with a 2.5% significance threshold. The other end
points are based on 2-sided testing with a 5% significance thresh-
old. Patients who had missing data for the test of cure were con-
sidered as having experienced treatment failure for both the in-
tention-to-treat and per-protocol analyses.
A prespecified sensitivity analysis, in which missing data
were treated as missing, was also performed. Additionally, post
hoc multiple imputation analysis was performed to address
missing data at the test-of-cure visit. A post hoc mixed-effects
analysis, treating site as a random effect, was performed to as-
sess for site effect. Except for the coprimary end points and the
antibiotic duration secondary end point, all other analyses were







Age, median (range), y 58 (19-91) 60 (18-94)
Men, No. (%) 146 (57.3) 137 (53.9)
Race, No. (%)a
White 175 (68.6) 174 (68.5)
Black or African American 63 (24.7) 60 (23.6)
Otherb 17 (6.7) 20 (7.9)
Ethnicity, No. (%)
Hispanic or Latino 21 (8.2) 23 (9.1)
Not Hispanic or Latino 234 (91.8) 231 (90.9)










Risk factor, No. (%)
Immunosuppressed conditiond 75 (29.4) 72 (28.3)
Diabetes mellitus 63 (24.7) 72 (28.3)
Chronic liver disease 25 (9.8) 20 (7.9)
Surgery within previous 30 d 24 (9.4) 20 (7.9)
Trauma within previous 30 d 9 (3.5) 12 (4.7)
Injection drug use 9 (3.5) 12 (4.7)
Preexisting valvular heart disease 9 (3.5) 9 (3.5)
Chronic renal insufficiency 8 (3.1) 5 (2.0)
History of S aureus infection
within the past year
7 (2.7) 5 (2.0)
Hypertrophic cardiomyopathy 5 (2.0) 6 (2.4)
Congenital heart disease 1 (0.4) 1 (0.4)
Previous infective endocarditis 0 0
Setting of infection, No. (%)
Nosocomial 85 (33.3) 82 (32.3)
Health care–associated,
community-onset
92 (36.1) 88 (34.6)
Community-acquired 78 (30.6) 84 (33.1)
Classification by diagnosis, No. (%)e
Simple or uncomplicated bacteremia 209 (81.9) 221 (87.0)
Simple coagulase-negative
staphylococci
136 (53.3) 124 (48.8)
Uncomplicated coagulase-negative
staphylococci
39 (15.3) 52 (20.5)
Uncomplicated S aureus 34 (13.3) 45 (17.7)
Complicated bacteremia 42 (16.4) 29 (11.4)
Complicated coagulase-negative
staphylococci
19 (7.5) 15 (5.9)
Complicated S aureus 23 (9.0) 14 (5.5)
Nonstaphylococcal infection 4 (1.6) 4 (1.6)
Echocardiogram performed, among
patients with S aureus, No./total (%)
56/57 (98.2) 58/59 (98.3)
Transesophageal echocardiogram 25/57 (43.9) 27/59 (45.8)
Diagnosed with endocarditisf 4/57 (7.0) 1 (1.7)
Median vancomycin minimum inhibitory
concentration, μg/mL
1.0 1.0





























catheter not removed, No. (%)h
1 (0.4) 2 (0.8)
S aureus treatment characteristics,
No./total (%)
Patients with S aureus receiving
appropriate empirical antibiotic
therapyi
57/57 (100) 58/59 (98.3)
MRSA receiving appropriate
empirical therapy
12/12 (100) 21/21 (100)
MSSA receiving appropriate
empirical therapy
45/45 (100) 37/38 (97.4)
MSSA receiving empirical
beta-lactam therapy
39/45 (86.7) 28/38 (73.7)
Infectious diseases consultation for S
aureus bacteremia
41/57 (71.9) 37/59 (62.7)
Abbreviations: IQR, interquartile range, MDRD, Modification of Diet in Renal
Disease; MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-susceptible Staphylococcus aureus.
a Race was determined by the investigators and based on predefined categories.
b The algorithm-based therapy group included 10 patients with race unknown
or not reported and 4 multiracial, 2 Asian, and 1 American Indian/Alaska Native
patients. The usual practice group included 12 patients with race unknown or
not reported and 4 Asian, 2 multiracial, 1 American Indian/Alaska Native, and 1
Native Hawaiian or other Pacific Islander patients.
c Calculated as weight in kilograms divided by height in meters squared.
d Defined as chronic low-dose (>10 mg prednisone for >50 d) or acute high-dose
(>40 mg prednisone for >7 d) corticosteroid administration or other
immunomodulatory agents (eg, monoclonal agents, methotrexate).
e This was the classification after the completion of the baseline evaluation,
including follow-up blood cultures and echocardiography. The patients with
complicated bacteremia were enrolled with suspected simple or
uncomplicated bacteremia but were subsequently found to have complicated
infection at baseline.
f Using the modified Duke criteria for diagnosis of endocarditis.9 Local site
interpretations and core laboratory echocardiogram interpretations resulted
in concordant endocarditis diagnoses (rejected, possible, or definite
endocarditis) in all cases.
g Vancomycin trough levels were not mandatory but were recorded when
obtained as part of routine care.
h Intravenous catheters could be retained in patients meeting a definition of
having simple coagulase-negative staphylococci. These 3 patients were
recorded as protocol deviations and were excluded from per-protocol analyses.
i Appropriate empiric therapy defined as treatment in the first 48 hours after
the index blood culture was drawn, with either vancomycin or daptomycin for
MRSA isolates and with vancomycin, daptomycin, or an antistaphylococcal
beta-lactam for MSSA isolates.
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not adjusted for multiple comparisons and should be inter-
preted as exploratory and hypothesis-generating.
All analyses were conducted using SAS version 9.4 (SAS
Institute Inc).
Data and Safety Monitoring Board
An independent data and safety monitoring board, ap-
pointed and managed by the National Institute of Allergy and
Infectious Diseases, regularly reviewed the data and made rec-
ommendations regarding study conduct.
Results
Patients
A total of 255 patients (146 [57.3%] men) were randomized to al-
gorithm-based therapy and 254 (137 [54.0%] men) to usual prac-
tice (Figure; eAppendix 3 in Supplement 2); 480 (94.3%) com-
pleted the trial (eTable 8 in Supplement 2). Demographic and
clinical characteristics in the 2 groups were similar (Table 2;
eTables 1-3 in Supplement 2). Among enrolled patients, 385 (76%)
had coagulase-negative staphylococcal bacteremia and 116 (23%)
had S aureus bacteremia. Blood cultures for 4 patients in each
group ultimately yielded only a nonstaphylococcal species.
Altogether, 260 patients had simple staphylococcal bac-
teremia, 170 had uncomplicated staphylococcal bacteremia
(91 coagulase-negative staphylococci, 79 S aureus), and 71
had complicated staphylococcal bacteremia (34 coagulase-
negative staphylococci, 37 S aureus). Eighty-four patients
with simple coagulase-negative staphylococcal bacteremia
were observed without antibiotic therapy.
Vancomycin MICs were similar in each group, with a me-
dian of 1 μg/mL. There were no S aureus isolates with vanco-
mycin MIC greater than 2 μg/mL.
Echocardiography was performed in all but 1 patient with
S aureus in each treatment group; transesophageal echocar-
diography was performed in 25 of 57 patients (43.9%) in the
algorithm-based therapy group and 27 of 59 (45.8%) in the
usual practice group. Definite endocarditis10 was diagnosed in
5 patients (4 algorithm, 1 usual practice). Blinded echocardi-
ography core laboratory interpretations were concordant with
local site interpretations.
Table 3. Outcomes at Test-of-Cure Visit
Criteria
No./Total No. (%)
Difference, % (1-Sided 97.5% CI)Algorithm-Based Therapy Usual Practice
Overall success in the ITT populationa 209/255 (82.0) 207/254 (81.5) 0.5 (−6.2 to )
Success according to assessment of complicationb
Simple or uncomplicated bacteremia 173/209 (82.8) 191/221 (86.4) −3.7 (−10.5 to 3.2)
Complicated bacteremia 36/42 (85.7) 16/29 (55.2) 30.5 (9.6 to 51.5)
Success according to clinical category
All Staphylococcus aureus 43/57 (75.4) 39/59 (66.1) 9.3 (−7.1 to )
Uncomplicated S aureus 24/34 (70.6) 34/45 (75.6) −5.0 (−24.8 to )
Complicated S aureus 19/23 (82.6) 5/14 (35.7) 46.9 (17.4 to )
All coagulase-negative staphylococci 166/194 (85.6) 168/191 (88.0) −2.4 (−9.2 to )
Simple coagulase-negative staphylococci 115/136 (84.6) 109/124 (87.9) −3.3 (−11.7 to )
Observed without antibiotics 37/46 (80.4) 35/38 (92.1) −11.7 (−26.0 to )
Treated with antibiotics 78/90 (86.7) 74/86 (86.0) 0.6 (−9.5 to )
Uncomplicated coagulase-negative staphylococci 34/39 (87.2) 48/52 (92.3) −5.1 (−17.9 to )
Complicated coagulase-negative staphylococci 17/19 (89.5) 11/15 (73.3) 16.1 (−10.2 to )
Overall success in the per-protocol population 185/207 (89.4) 178/203 (87.7) 1.7 (−4.5 to )
Success according to pathogen in the ITT populationc
S aureus
Methicillin-susceptible 33/45 (73.3) 23/38 (60.5) 12.8 (−7.4 to )
Methicillin-resistant 10/12 (83.3) 16/21 (76.2) 7.1 (−20.7 to )
Coagulase-negative staphylococci
Methicillin-susceptible 81/90 (90.0) 82/88 (93.2) −3.2 (−11.3 to )
Methicillin-resistant 84/98 (85.7) 86/100 (86.0) −0.3 (−10.0 to )
Abbreviation: ITT, intention-to-treat.
a In a sensitivity analysis in which missing data were treated as missing, results
were similar (success, 209/223 [93.7%] in the algorithm-based therapy group
vs 207/221 [93.7%] in the usual practice group; difference, 0.1 [1-sided 97.5%
CI, −4.5 to ]). In the post hoc multiple imputation analysis, results were also
similar (difference, 0.2 [1-sided 97.5% CI, −5.6 to ]). See also eTable 6 in
Supplement 2.
b Final classification as simple, uncomplicated, or complicated bacteremia was
established after completion of the baseline evaluation, including follow-up
blood cultures and echocardiography. Patients with complicated bacteremia
were enrolled with suspected simple or uncomplicated bacteremia but were
subsequently found to have complicated infection at baseline.
c Methicillin susceptibility testing was not available for 9 (2.3%)
coagulase-negative staphylococci isolates (5 with simple coagulase-negative
staphylococci and 1 with uncomplicated coagulase-negative staphylococci in
the algorithm-based therapy group, and 2 with simple coagulase-negative
staphylococci and 1 with uncomplicated coagulase-negative staphylococci in
the usual practice group).
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Primary Outcomes
In the intention-to-treat population, clinical success oc-
curred in 209 of 255 patients in the algorithm group and 207
of 254 in the usual practice group (82.0% vs 81.5%; differ-
ence, 0.5% [1-sided 97.5% CI, −6.2% to ]) (Table 3; eTables 4
and 5 in Supplement 2). Since the lower limit of the confi-
dence interval was greater than −15%, algorithm-based therapy
was determined to be noninferior to usual practice. There were
65 patients (12.8%) missing the primary efficacy end point. Sen-
sitivity analyses in which missing data were treated as miss-
ing, as well as post hoc multiple imputation analysis and mixed-
effects analysis treating site as a random effect, were consistent
with the primary analysis (Table 3; eTable 6 in Supplement 2).
The overall serious adverse event frequency was not sig-
nificantly different in the algorithm and usual practice groups
(32.5% vs 28.3%; difference, 4.2% [95% CI, −3.8% to 12.2%]).
Adverse events leading to study drug discontinuation were re-
ported in 4 patients in the algorithm group and 1 in the usual
practice group (Table 4; eTable 7 in Supplement 2). Although
161 of 509 patients (31.6%) had at least 1 adverse event, ad-
verse events related to study drug were infrequent (14/509
[2.8%]). A total of 16 patients (6.3%) in the algorithm-based
therapy group and 14 (5.5%) in the usual practice group died
before the test-of-cure assessment (difference, 0.8% [95% CI,
−3.3% to 4.9%]). The blinded adjudication committee attrib-
uted 2 of the deaths in the algorithm group to infection, com-
pared with 3 in the usual practice group; all of these deaths were
among patients with S aureus infection (Table 4). Serious ad-
verse events related to infections occurred in 10.6% of pa-
tients in the algorithm group, compared with 11.0% in the usual
practice group.
Secondary Outcome
Among per-protocol patients with simple or uncomplicated
bacteremia, duration of therapy was significantly shorter in the
algorithm-based therapy group than in the usual practice group
(4.4 days vs 6.2 days; difference, −1.8 days [95% CI, −3.1 to −0.6
days]) (Table 5; eTable 8 in Supplement 2). This difference was
primarily attributable to shorter duration of therapy in pa-
tients in the algorithm-based therapy group who had uncom-
plicated coagulase-negative staphylococcal bacteremia (5.3
days vs 8.4 days; difference, −3.1 days [95% CI, −4.9 to −1.3
days]). When the group of patients with simple coagulase-
negative staphylococcal bacteremia who were observed with-
out antibiotic therapy were excluded from the analysis, dura-
tion of therapy remained significantly shorter in the algorithm
group (5.8 days vs 7.7 days; difference, −1.9 days [95% CI, −3.4
to −0.5 days]).
Exploratory Outcomes
Within prespecified subgroup analyses, success rates were not
significantly different among patients with simple coagulase-
negative staphylococcal bacteremia; uncomplicated coagulase-
negative staphylococcal bacteremia; and uncomplicatedS aureus
bacteremia (Table 3; eTables 9 and 10 in Supplement 2).
Among patients with simple coagulase-negative staphy-
lococci in both the algorithm and the usual practice groups,
clinical success occurred in 72 of 84 patients (85.7%) who re-




Serious adverse events in the
ITT population, No./total (%)a
83/255 (32.5) 72/254 (28.3)
Mortality, No./total (%)b,c 16/255 (6.3) 14/254 (5.5)
No. related to infection
per blinded adjudication/
total deaths (%)

















Complicated S aureus 1/2 2/3
Serious adverse events
by organ system class, No. (%)d
n = 255 n = 254
Infections and infestations 27 (10.6) 28 (11.0)
Renal and urinary disorders 12 (4.7) 4 (1.6)
Respiratory, thoracic,
and mediastinal disorders
10 (3.9) 13 (5.1)
Blood and lymphatic
system disorders
9 (3.5) 7 (2.8)




8 (3.1) 6 (2.4)
Cardiac disorders 8 (3.1) 5 (2.0)
Metabolism and
nutrition disorders




6 (2.4) 4 (1.6)
Vascular disorders 5 (2.0) 2 (0.8)
Nervous system disorders 4 (1.6) 6 (2.4)
Psychiatric disorders 4 (1.6) 3 (1.2)
Investigations 4 (1.6) 1 (0.4)
Neoplasms 3 (1.2) 3 (1.2)
Hepatobiliary disorders 3 (1.2) 3 (1.2)
Musculoskeletal and
connective tissue disorders
2 (0.8) 2 (0.8)




Endocrine disorders 1 (0.4) 0





with study drug, No. (%)
9 (3.5) 5 (2.0)
Adverse events leading
to study drug discontinuation,
No. (%)
4 (1.6) 1 (0.4)
Abbreviation: ITT, intention-to-treat.
a Difference, 4.2% (95% CI, −3.8% to 12.2%).
b Difference, 0.8% (95% CI, −3.3% to 4.9%).
c No patients died during study antibiotic therapy.
d Patients could have more than 1 event.
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ceived no antibiotic therapy, compared with 152 of 176 (86.4%)
who received antibiotics.
Among patients with uncomplicated S aureus bacte-
remia, 21 of 79 (26.6%) were classified as having experienced
treatment failure. Of these, 9 (11.4%) were classified as expe-
riencing failure because of nonevaluable status, whereas 12
(15.2%) experienced clinical failure (eTable 4 in Supplement 2).
In a post hoc analysis of patients with complicated S aureus
bacteremia, success rates were higher in the algorithm group
(19/23 [82.6%] vs 5/14 [35.7%]; difference, 46.9% [1-sided 97.5%
CI, 17.4% to ]). No significant differences were identified in
success rates by methicillin susceptibility or by vancomycin
MIC of the bloodstream isolate.
Discussion
In this study, among patients with staphylococcal bacte-
remia, the use of an algorithm to guide testing and treatment
compared with usual care resulted in a noninferior rate of clini-
cal success. There was no significant difference in rates of se-
rious adverse events, although the upper bound of the 95% con-
fidence interval suggests the possibility of a higher rate of
adverse events with abbreviated therapy.
Algorithm-based therapy reduced median antibiotic dura-
tion by 29%, compared with usual practice, for evaluable pa-
tients with simple or uncomplicated bacteremia. The differ-
ence was most notable among patients with uncomplicated
coagulase-negative staphylococcal bacteremia, for whom an-
tibiotic duration was reduced by 3.1 days (37%). Consensus
guidelines recommend short-course antibiotic therapy of 5 to
7 days for uncomplicated coagulase-negative staphylococcal
catheter-related bacteremia.4 However, to our knowledge, be-
fore the current study there were no randomized trial data to
support these recommendations. The results of this study also
provide evidence that simple coagulase-negative staphylococ-
cal bacteremia, which is frequently regarded as a contaminant,11
may not require antibiotic therapy.
The essential risk of abbreviated therapy is undertreated
infection, which would be expected to manifest as any or all
of the following: lower cure rates, higher relapse rates, and
higher rates of infection-related adverse events, including mor-
tality. In this trial, in addition to noninferior clinical success
rates, use of the algorithm was not significantly associated with
more infection-related severe adverse events. Although the dif-
ference in overall mortality was not statistically significant, the
upper confidence limit was 4.9% worse in patients random-
ized to the algorithm. While the blinded adjudication com-
mittee attributable mortality outcome was not a prespecified
end point, the committee attributed fewer deaths to infec-
tion in the algorithm group. The relatively high rate of seri-
ous adverse events experienced by patients in this trial may
therefore reflect the severity of concurrent illnesses among hos-
pitalized patients with staphylococcal bacteremia.
The duration of therapy for uncomplicated S aureus bac-
teremia has been a point of controversy since at least 1976,
when 10 to 21 days was proposed for S aureus bacteremia as-
sociated with a removable focus of infection.12 A meta-
analysis evaluating the duration of therapy for catheter-
associated S aureus bacteremia found that the complication
rate of short-course therapy (defined as 2 weeks) was 6.1% and
concluded that durations of antibiotics longer than 2 weeks
should be used until a means exists to accurately identify pa-
tients with underlying complications.7 In the current study, pa-
tients randomized to algorithm-based therapy or usual prac-
tice for uncomplicated S aureus bacteremia had similar
durations of therapy (≈15 days), suggesting that 2 weeks of
therapy may be a standard medical practice for this diagnosis
in many centers. Despite the widespread acceptance of this
treatment duration, however, approximately 15% of the pa-
tients with uncomplicated S aureus bacteremia in the study
were classified as having experienced treatment failure for non-
administrative reasons (antibiotic therapy changed because of
an unsatisfactory clinical response, new metastatic infec-
tion, persistent or relapsing infection, or death). In addition,
32% of study patients with S aureus bacteremia without sus-
pected metastatic infection at enrollment were ultimately di-
agnosed with complicated S aureus bacteremia. Collectively,
these results suggest that a 2-week course of therapy for un-
complicated S aureus bacteremia should be used with cau-
tion and only if patients have undergone a careful evaluation
for metastatic infection.2-4,13
Patients with complicated S aureus bacteremia in the al-
gorithm group experienced higher cure rates than those in the
Table 5. Duration of Therapy Among Per-Protocol Patients With Simple or Uncomplicated Staphylococcal Bacteremiaa
Algorithm-Based Therapy Usual Practice
Difference of Means, d
(95% CI)Mean Median (IQR) No. Mean Median (IQR) No.
Duration of therapy, d 4.4 3.0 (1.0 to 5.0) 171 6.2 3.0 (1.0 to 13.0) 183 −1.8 (−3.1 to −0.6)
Simple coagulase-negative
staphylococci




5.3 5.0 (5.0 to 6.0) 33 8.4 7.5 (5.0 to 14.0) 42 −3.1 (−4.9 to −1.3)
Uncomplicated
Staphylococcus aureus
15.3 14.0 (14.0 to 15.0) 24 15.9 16.0 (14.0 to 17.0) 38 −0.6 (−3.4 to 2.2)
Abbreviation: IQR, interquartile range.
a In an exploratory analysis in patients with complicated bacteremia, patients
with complicated coagulase-negative staphylococci had a mean duration of
therapy of 10.6 days (median, 9.0; IQR, 7.0-13.0) in algorithm-based therapy
and 14.5 days (median, 13.0; IQR, 10.0-16.0) in usual practice (difference of
means, 3.9 days [95% CI, −8.9 to 1.1]). Patients with complicated S aureus
bacteremia had a mean duration of therapy of 30.2 days (median, 29.0;
IQR, 24.0-33.0) in algorithm-based therapy and 27.5 days (median, 31.0;
IQR, 17.0-33.0) in usual practice (difference of means, 2.7 days [95% CI, −3.9 to
9.3]). Additional information is available in eTables 4 and 5 in Supplement 2.
Research Original Investigation Algorithm-Based Therapy vs Usual Care for Patients with Staphylococcal Bacteremia
1256 JAMA September 25, 2018 Volume 320, Number 12 (Reprinted) jama.com
© 2018 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ on 04/15/2020
usual practice group. While this is an exploratory subgroup
analysis and may reflect chance, it is consistent with other re-
cent studies14 and suggests that this algorithm incorporates a
comprehensive set of management principles that can im-
prove outcomes for patients with S aureus bacteremia.14
Limitations
This study had several limitations. First, this study was delib-
erately not powered to compare subgroups such as patients
with uncomplicated S aureus bacteremia. Instead, it was de-
signed and powered to address a more clinically applicable
question: how to define the optimal treatment duration for a
patient with staphylococcal bacteremia and no evidence of
metastatic infection. Second, the open-label design of the study
could have introduced bias.15 However, primary study end
points were established by a blinded adjudication commit-
tee. Third, repeated exposure to the algorithm may have in-
fluenced management decisions in clinicians caring for pa-
tients receiving algorithm-based therapy as well as those
receiving usual practice. This possibility is suggested by simi-
lar durations of therapy in the patients with uncomplicated
S aureus bacteremia in both treatment groups. However, this
potential bias would have underestimated the difference in du-
ration of therapy between algorithm-based therapy and usual
practice. Fourth, intravenous catheters were removed in all pa-
tients except those with simple coagulase-negative staphylo-
coccal bacteremia. Thus, this trial does not establish the op-
timal duration of therapy for patients with staphylococcal
bacteremia in whom a catheter-retention strategy is pur-
sued. Fifth, this study was conducted at academic institu-
tions. Thus, medical practices in the study may not reflect those
of other health care organizations.
Conclusions
Among patients with staphylococcal bacteremia, the use of an
algorithm to guide testing and treatment compared with usual
care resulted in a noninferior rate of clinical success. Rates of
serious adverse events were not significantly different, but in-
terpretation is limited by wide confidence intervals. Further
research is needed to assess the utility of the algorithm.
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